MOLN Stock Forecast & Price Target

Molecular Partners is a promising biopharmaceutical company with a strong focus on developing protein therapeutics for the treatment of serious diseases, especially in the field of oncology. The company has a robust pipeline with MP0712, a Radio-DARPin candidate targeting DLL3, currently in a Phase 1/2a trial in the United States. Despite potential risks such as negative clinical data and competition, Molecular Partners has a potential market value of $502M and its targeted radionuclide therapy (TRT) shows promise in various therapeutic targets and indications. Additionally, the company has strong financials and valuable patents that could protect its assets until the 2040s.

Molecular Partners is a clinical-stage biopharmaceutical company with a primary focus in oncology through a pipeline of clinical and preclinical programs, with its lead candidate MP0712 targeting DLL3 currently in a Phase 1/2a trial in the U.S. Financially, the company reported cash and cash equivalents of approximately $116 million at the end of 2025, and we forecast net losses per share of CHF1.63 and CHF1.32 for 2025 and 2026, respectively. However, due to the early stage of their assets and lack of clinical data, we assign a low 15% probability of approval for MP0712 and project the company may not achieve profitability until after 2030, dependent on clinical and regulatory success. Furthermore, the biopharma industry is inherently volatile and subject to government regulations, which may affect operations and is discussed further in the company's SEC filings.